Roger Storms - Puma Biotechnology Senior Sales
| PBYI Stock | USD 5.91 0.08 1.37% |
Executive
Roger Storms is Senior Sales of Puma Biotechnology
| Address | 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 |
| Phone | 424 248 6500 |
| Web | https://www.pumabiotechnology.com |
Puma Biotechnology Management Efficiency
The company has return on total asset (ROA) of 0.099 % which means that it generated a profit of $0.099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3969 %, meaning that it created $0.3969 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The Puma Biotechnology's current Return On Tangible Assets is estimated to increase to 0.20. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.28. As of now, Puma Biotechnology's Debt To Assets are increasing as compared to previous years. The Puma Biotechnology's current Fixed Asset Turnover is estimated to increase to 47.51, while Total Assets are projected to decrease to under 168.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lisa McClainMoss | Longeveron LLC | 54 | |
| Ruben JD | FibroBiologics, Common Stock | 48 | |
| Jennifer Kiang | Dare Bioscience | N/A | |
| Robert Renninger | Athira Pharma | 40 | |
| Samantha Willing | Athira Pharma | N/A | |
| Dhananjay Wadekar | Citius Pharmaceuticals | 71 | |
| Kevin Church | Athira Pharma | 40 | |
| MS MD | Aditxt Inc | N/A | |
| Lisa Locklear | Longeveron LLC | 63 | |
| Paul JD | Longeveron LLC | 57 | |
| Mark JD | Athira Pharma | 59 | |
| Christopher Porcelli | Aditxt Inc | N/A | |
| Myron MD | Citius Pharmaceuticals | 65 | |
| Catherine MS | Citius Pharmaceuticals | N/A | |
| Ruben Garcia | FibroBiologics, Common Stock | N/A | |
| MD FACP | Moleculin Biotech | 72 | |
| Ilanit Allen | Citius Pharmaceuticals | N/A | |
| Dr D | Aditxt Inc | N/A | |
| David JD | Pulmatrix | 66 | |
| Hamid Khoja | FibroBiologics, Common Stock | 55 | |
| Mark Walters | Dare Bioscience | 70 | |
Management Performance
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 |
Puma Biotechnology Leadership Team
Elected by the shareholders, the Puma Biotechnology's board of directors comprises two types of representatives: Puma Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Puma. The board's role is to monitor Puma Biotechnology's management team and ensure that shareholders' interests are well served. Puma Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Puma Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Ludwig, Chief Officer | ||
| Roger Storms, Senior Sales | ||
| Maximo Nougues, CFO Officer | ||
| Alan Auerbach, Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee | ||
| Alvin Pharmd, Chief Officer | ||
| Heather Blaber, Senior Marketing | ||
| FRAPS BSc, Pharmacovigilance, Affairs | ||
| Mariann Ohanesian, Senior Director, Investor Relations | ||
| Bo Chao, Senior Development |
Puma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Puma Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 240.44 M | ||||
| Shares Outstanding | 50.39 M | ||||
| Shares Owned By Insiders | 15.38 % | ||||
| Shares Owned By Institutions | 71.42 % | ||||
| Number Of Shares Shorted | 3.41 M | ||||
| Price To Earning | 18.52 X |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.77 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.